Search Results | Blood | American Society of Hematology

1-20 of 880

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Blood (2019) 134 (Supplement_1): 2458.

DOI: https://doi.org/10.1182/blood-2019-127176

Published: 2019

Journal Articles

Prediction for the Risk of Gvhd after Allogeneic HSCT in Patients with ATL Treated By Mogamulizumab

Yuhei Kamada, MD PhD, Ayako Kuroki, PhD, Naosuke Arima, MD, Maiko Hayashida, MD, Daisuke Nakamura, MD PhD, Makoto Yoshimitsu, MD PhD, Kenji Ishitsuka, MD PhD

Blood (2019) 134 (Supplement_1): 3290.

DOI: https://doi.org/10.1182/blood-2019-126912

Published: 2019

Journal Articles

Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies

Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Tayyab Rehan, MBBS, Muhaddis Ejaz Ahmad, MD, Syeda Sabeeka Batool, MBBS, MD, Muhammad Abdullah Yousaf, MBBS, MD, Maaz Ahmed Yusufi, MD, Saif Ur Rehman, MBBS, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Zainab Ijaz, Awais Ijaz, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 4442.

DOI: https://doi.org/10.1182/blood-2019-127452

Published: 2019

Journal Articles

Sickle Cell Disease Post-Transplant Care Challenges in Nigeria: Systematic Institutional Neglect of Medical Tourism

Adeseye Michael Akinsete, MBBS, Michael R. DeBaun, MDMPH, Adetola A. Kassim, MDMS

Blood (2019) 134 (Supplement_1): 4568.

DOI: https://doi.org/10.1182/blood-2019-126120

Published: 2019

Journal Articles

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Arie Apel, MD, Yishay Ofran, MD, Avraham Frisch, MD, Yakir Moshe, MD, Ofir Wolach, MD, Chiya Leibovitch, MD, Natalia Kreiniz, MD, Maya Koren-Michowitz, MD

Blood (2019) 134 (Supplement_1): 3902.

DOI: https://doi.org/10.1182/blood-2019-125720

Published: 2019

Journal Articles

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Mariela Rodriguez, MD, Ronald Rojas, Alejandra Vargas, MD, Miguel Angel Rodriguez, MD, Claudia Garcia, MD, Juliana Esquivel, MD, Jose Gerardo Rojas, MD, Willem Bujan Boza, MD

Blood (2019) 134 (Supplement_1): 3838.

DOI: https://doi.org/10.1182/blood-2019-122627

Published: 2019

Journal Articles

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Feng Zhu, Yongxian Hu, MD, Wei Guoqing, He Huang, Wenjun Wu, MD

Blood (2019) 134 (Supplement_1): 3220.

DOI: https://doi.org/10.1182/blood-2019-129649

Published: 2019

Journal Articles

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1609.

DOI: https://doi.org/10.1182/blood-2019-131499

Published: 2019

Journal Articles

Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders

Luis E Malpica Castillo, MD, Shannon Palmer, MS, Anqi Zhu, MS, Allison Deal, MS, Sheh-Li Chen, PharmD, Stephan Moll, MD

Blood (2019) 134 (Supplement_1): 792.

DOI: https://doi.org/10.1182/blood-2019-121340

Published: 2019

Journal Articles

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Blood (2019) 134 (Supplement_1): 5644.

DOI: https://doi.org/10.1182/blood-2019-130914

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

DOI: https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

Guillaume Richard-Carpentier, MD, Amy E. DeZern, MD, Koichi Takahashi, MD, Marina Y Konopleva, MD PhD, Sanam Loghavi, MD, Lucia Masarova, MD, Yesid Alvarado, MD, Farhad Ravandi, MD, Guillermo Montalban Bravo, MD, Kiran Naqvi, MDMPH, Koji Sasaki, MD, Ricardo Delumpa, BSN, Monica Kwari, BSN, Mikkael A. Sekeres, MD MS, Aziz Nazha, MD, Gail J. Roboz, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Courtney D. DiNardo, MD MSc

Blood (2019) 134 (Supplement_1): 678.

DOI: https://doi.org/10.1182/blood-2019-130501

Published: 2019

Journal Articles

Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry

Blood (2019) 134 (Supplement_1): 4180.

DOI: https://doi.org/10.1182/blood-2019-125864

Published: 2019

Journal Articles

Immediate and Long-Term Outcomes Following Orthopedic Procedures in Patients with Hemophilia: A Three-Decade Retrospective Review

CHU Yang Lin, MD, Haowei Sun, MD

Blood (2019) 134 (Supplement_1): 5874.

DOI: https://doi.org/10.1182/blood-2019-123207

Published: 2019

Journal Articles

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Melhem Solh, MD, Scott R. Solomon, MD, H. Kent Holland, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 4479.

DOI: https://doi.org/10.1182/blood-2019-131624

Published: 2019

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

DOI: https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants

Cristina F Contreras, BS, Janel R Long-Boyle, PharmD, PhD, Kristin A. Shimano, MD, Jasmeen Dara, MD, James N Huang, MD, Sandhya Kharbanda, MD, Alexis Melton, MD PhD, Christine Higham, MD, Morton J Cowan, MD, Christopher C. Dvorak, MD

Blood (2019) 134 (Supplement_1): 4481.

DOI: https://doi.org/10.1182/blood-2019-127218

Published: 2019

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

DOI: https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

Primary Antigen Aberrations and Immunophenotype Shifts of Blasts in AML Patients during the Treatment and at the Time of Relapse

Tatiana I. Lobanova, MD, Elena N. Parovichnikova, MD PhD, Irina V. Galtseva, MD PhD, Vera V. Troitskaya, MD PhD, Julia O. Davydova, Nikolay M. Kapranov, Andrey N. Sokolov, MD PhD, Sergei M. Kulikov, PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5183.

DOI: https://doi.org/10.1182/blood-2019-128650

Published: 2019

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Blood (2019) 134 (Supplement_1): 357.

DOI: https://doi.org/10.1182/blood-2019-131939

Published: 2019

2 3 4 5

NARROW

Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody

Prediction for the Risk of Gvhd after Allogeneic HSCT in Patients with ATL Treated By Mogamulizumab

Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies

Sickle Cell Disease Post-Transplant Care Challenges in Nigeria: Systematic Institutional Neglect of Medical Tourism

Safety and Efficacy of First Line Venetoclax Combinations in AML Patients Ineligible for Intensive Therapy, a Real World Data

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic Disorders

Comparison of Early Versus Delayed Filgrastim (G-CSF) Administration Following Autologous Stem Cell Transplantation in Patients with Multiple Myeloma - Real-World Data from a Single-Center Institution

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2 -Mutated Myelodysplastic Syndromes (MDS)

Analysis of Predictive Factors for Early Response to Ruxolitinib in 266 Patients with Myelofibrosis from the Polish Adult Leukemia Group (PALG) Registry

Immediate and Long-Term Outcomes Following Orthopedic Procedures in Patients with Hemophilia: A Three-Decade Retrospective Review

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Infectious Complications Associated with CAR T-Cell Therapy

Reduced Toxicity Conditioning for Non-Malignant Hematopoietic Cell Transplants

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Primary Antigen Aberrations and Immunophenotype Shifts of Blasts in AML Patients during the Treatment and at the Time of Relapse

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only